Next Article in Journal
Seroprevalence Study of Anti-HEV IgG among Different Adult Populations in Corsica, France, 2019
Next Article in Special Issue
Inflammatory Immune Responses in Patients with Tick-Borne Encephalitis: Dynamics and Association with the Outcome of the Disease
Previous Article in Journal
CRISPR/Cas9-Mediated Gene Replacement in the Fungal Keratitis Pathogen Fusarium solani var. petroliphilum
Previous Article in Special Issue
Phylogenetic Analysis of Lednice Orthobunyavirus
Open AccessArticle

A Dengue Vaccine: Will It be Accepted and Is It Feasible? Lessons from Barranquilla, Colombia, and Merida, Venezuela

1
Department of Medicine, The George Washington University, Washington, DC 20037, USA
2
Allied Research Society, LLC, Barranquilla, Atlántico 080001, Colombia
3
Fundación Hospital Universitario Metropolitano, Barranquilla, Atlántico 080001, Colombia
4
Departament of clinical microbiology and parasitology, Universidad de los Andes, Merida, Estado Merida 5101, Venezuela
5
Department of Internal Medicine, Universidad Simón Bolívar, Barranquilla, Atlántico 080002, Colombia
6
Clinica de La Costa LTDA, Barranquilla, Atlántico 080001, Colombia
*
Author to whom correspondence should be addressed.
Microorganisms 2019, 7(10), 458; https://doi.org/10.3390/microorganisms7100458
Received: 17 September 2019 / Revised: 8 October 2019 / Accepted: 9 October 2019 / Published: 16 October 2019
(This article belongs to the Special Issue Emerging Vector Borne Infections: A Novel Threat for Global Health)
With one vaccine on the market and others in clinical trials, policy makers in dengue endemic regions face the decision of whether to introduce a dengue vaccine in their communities. The World Health Organization (WHO) recommends that individualized assessments be conducted before any vaccine introduction to evaluate disease burden and the strength of current vaccination programs. This study seeks to aid in that decision-making process by examining the acceptability and feasibility of dengue vaccine introduction in Barranquilla, Colombia, and Merida, Venezuela. Surveys were administered February–June of 2018 for three groups: patients (n = 351), health professionals (n = 197), and government officials (n = 26). In Barranquilla, most respondents reported dengue to be a moderate-severe problem, that a dengue vaccine would be useful in their communities, and that their current vaccination programs could handle the addition of a new vaccine. In Venezuela, respondents were less likely to view dengue as a major concern and listed multiple barriers to not just dengue vaccine introduction, but to providing current vaccines as well. Further work is needed in Colombia to more objectively assess the country’s readiness as a whole for a future dengue vaccine. As political and social unrest continues in Venezuela, however, future initiatives should focus on trust and capacity building. This study can serve as a framework for future assessments of the acceptability and feasibility of a dengue vaccine in both targeted areas and on larger scales. View Full-Text
Keywords: dengue vaccines; feasibility studies; Colombia; venezuela dengue vaccines; feasibility studies; Colombia; venezuela
Show Figures

Figure 1

MDPI and ACS Style

McMahon, E.; Encinales, L.; Navarro Encinales, C.; Vielma, S.; Pacheco, N.; Avendaño Echavez, L.G.; Acosta Rodríguez, S.; Calderon, M.; Encinales Sanabria, S.; Encinales Sanabria, L.; Serrano Bernal, E.; Gonzaléz Coba, A.; Jiménez, D.; Simon, G.; Chang, A.Y. A Dengue Vaccine: Will It be Accepted and Is It Feasible? Lessons from Barranquilla, Colombia, and Merida, Venezuela. Microorganisms 2019, 7, 458.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop